Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer
Open Access
- 1 August 2020
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 485, 1-13
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
This publication has 143 references indexed in Scilit:
- A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancerInvestigational New Drugs, 2012
- A Central Role for mTOR Kinase in Homeostatic Proliferation Induced CD8+ T Cell Memory and Tumor ImmunityImmunity, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and MetabolismImmunity, 2010
- Alternative Activation of Macrophages: Mechanism and FunctionsImmunity, 2010
- mTOR regulates memory CD8 T-cell differentiationNature, 2009
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage CommitmentImmunity, 2009
- Immunoregulatory functions of mTOR inhibitionNature Reviews Immunology, 2009
- Molecular mechanisms of mTOR-mediated translational controlNature Reviews Molecular Cell Biology, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008